FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2043962964> ?p ?o ?g. }

• W2043962964 endingPage "1203" @default.
• W2043962964 startingPage "1190" @default.
• W2043962964 abstract "Background Efficacy of blood pressure (BP) lowering may differ between clinical trials and what is observed in clinical practice. These differences may contribute to poor BP control rates among those at risk. Objective We conducted an observational study to determine the BP-lowering efficacy of angiotensin receptor blocker (ARB) versus non–ARB-based antihypertensive treatments in a large Canadian primary care database. Methods We analyzed the South Western Ontario database of 170,000 adults (aged >18 years) with hypertension persisting with antihypertensive medication for ≥9 months. Routine standard of care office BP was measured using approved manual aneroid or automated devices. BP <140 mm Hg and/or <90 mm Hg ≤9 months after treatment initiation, persistence (presence of initial antihypertensive prescription at the first, second, third, and fourth year anniversary) with antihypertensive therapy, and the presence of a cardiovascular (CV) event (ie, myocardial infarction) were studied. Results After 9 months of monotherapy, 28% (978 of 3490) of patients on ARBs achieved target BP versus 27% (839 of 3110) on angiotensin-converting enzyme inhibitors (ACEIs) (P > 0.05), 26% (265 of 1020) on calcium channel blockers (CCBs) (P > 0.05), 21% (221 of 1050) on β-blockers (P = 0.002), and 19% (276 of 1450) on diuretics (P = 0.001). Attainment rates were significantly higher with irbesartan (38%; 332 of 873) versus losartan (32%; 335 of 1047; P = 0.01), valsartan (19%; 186 of 977; P = 0.001), and candesartan (25%; 148 of 593; P = 0.001). BP goal attainment rates were significantly higher when ARB was compared with non–ARB-based dual therapy (39%; 1007 of 2584 vs 31%; 1109 of 3576; P = 0.004); irbesartan + hydrochlorothiazide (HCTZ) was significantly higher than losartan + HCTZ (36%; 500 of 1390 vs 20%; 252 of 1261; P = 0.001). For patients receiving dual or tri-therapy, 48% (667 of 1390) of patients receiving irbesartan reached target BP versus 41% to 42% for losartan (517 of 1261), valsartan (194 of 462), and candesartan (168 of 401) (P = 0.001 for each). After 4 years, persistence rates were not statistically different among ARB, CCB, and diuretic monotherapies, but appeared somewhat higher with ACEIs and β-blockers (78%, 78%, 79%, 91%, and 84%, respectively). Persistence was not significantly different between irbesartan and losartan monotherapy (76% for both; P > 0.05), but was significantly higher with irbesartan + HCTZ versus losartan + HCTZ (96% vs 73%, respectively; P = 0.001). Patients treated with ARBs reported fewer CV events than those receiving ACEIs or CCBs (4.3% vs 7.0% and 11.0%, respectively; P < 0.001). Within the ARB class, the lowest rate was with irbesartan (3.0% vs 4.6%–5.0% for other ARBs; P < 0.02). Conclusions In this real-world setting, hypertensive adults treated with ARBs versus β-blockers or diuretics were more likely to have evidence-based target BP recorded. In addition, patients using ARBs versus ACEIs or CCBs had fewer reports of CV events." @default.
• W2043962964 created "2016-06-24" @default.
• W2043962964 creator A5069438360 @default.
• W2043962964 creator A5070128588 @default.
• W2043962964 date "2011-09-01" @default.
• W2043962964 modified "2023-10-18" @default.
• W2043962964 title "Retrospective Analysis of Real-World Efficacy of Angiotensin Receptor Blockers Versus Other Classes of Antihypertensive Agents in Blood Pressure Management" @default.
• W2043962964 cites W157136288 @default.
• W2043962964 cites W1579286767 @default.
• W2043962964 cites W1966354075 @default.
• W2043962964 cites W1971980764 @default.
• W2043962964 cites W1974103732 @default.
• W2043962964 cites W1977247124 @default.
• W2043962964 cites W1979030376 @default.
• W2043962964 cites W1980678039 @default.
• W2043962964 cites W1981548230 @default.
• W2043962964 cites W19849081 @default.
• W2043962964 cites W1986541063 @default.
• W2043962964 cites W1986893063 @default.
• W2043962964 cites W1991078342 @default.
• W2043962964 cites W1993731981 @default.
• W2043962964 cites W1997980688 @default.
• W2043962964 cites W2003042623 @default.
• W2043962964 cites W2006128309 @default.
• W2043962964 cites W2012608392 @default.
• W2043962964 cites W2019189773 @default.
• W2043962964 cites W202007523 @default.
• W2043962964 cites W2021011733 @default.
• W2043962964 cites W2028633414 @default.
• W2043962964 cites W2034946996 @default.
• W2043962964 cites W2039451330 @default.
• W2043962964 cites W2040445085 @default.
• W2043962964 cites W2041392492 @default.
• W2043962964 cites W2044773944 @default.
• W2043962964 cites W2049258388 @default.
• W2043962964 cites W2055481333 @default.
• W2043962964 cites W2056893352 @default.
• W2043962964 cites W2056976690 @default.
• W2043962964 cites W2060554337 @default.
• W2043962964 cites W2064790183 @default.
• W2043962964 cites W2065216055 @default.
• W2043962964 cites W2065967117 @default.
• W2043962964 cites W2066291670 @default.
• W2043962964 cites W2066894046 @default.
• W2043962964 cites W2068519950 @default.
• W2043962964 cites W2069093445 @default.
• W2043962964 cites W2074483651 @default.
• W2043962964 cites W2080973197 @default.
• W2043962964 cites W2082995815 @default.
• W2043962964 cites W2090798025 @default.
• W2043962964 cites W2091894592 @default.
• W2043962964 cites W2093273906 @default.
• W2043962964 cites W2095637793 @default.
• W2043962964 cites W2098392215 @default.
• W2043962964 cites W2098780362 @default.
• W2043962964 cites W2116766667 @default.
• W2043962964 cites W2124129401 @default.
• W2043962964 cites W2129991662 @default.
• W2043962964 cites W2130136596 @default.
• W2043962964 cites W2131494018 @default.
• W2043962964 cites W2133217116 @default.
• W2043962964 cites W2133617016 @default.
• W2043962964 cites W2135038122 @default.
• W2043962964 cites W2137408480 @default.
• W2043962964 cites W2137978158 @default.
• W2043962964 cites W2139024953 @default.
• W2043962964 cites W2140941743 @default.
• W2043962964 cites W2152798629 @default.
• W2043962964 cites W2154798443 @default.
• W2043962964 cites W2155828626 @default.
• W2043962964 cites W2156121263 @default.
• W2043962964 cites W2156867561 @default.
• W2043962964 cites W2157677292 @default.
• W2043962964 cites W2159729565 @default.
• W2043962964 cites W2160547085 @default.
• W2043962964 cites W2162544110 @default.
• W2043962964 cites W2167732511 @default.
• W2043962964 cites W2172032309 @default.
• W2043962964 cites W2303651371 @default.
• W2043962964 cites W2318871790 @default.
• W2043962964 cites W2615043561 @default.
• W2043962964 cites W2912928282 @default.
• W2043962964 cites W3034899365 @default.
• W2043962964 cites W4255660305 @default.
• W2043962964 cites W75245760 @default.
• W2043962964 cites W7687383 @default.
• W2043962964 doi "https://doi.org/10.1016/j.clinthera.2011.08.008" @default.
• W2043962964 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21885126" @default.
• W2043962964 hasPublicationYear "2011" @default.
• W2043962964 type Work @default.
• W2043962964 sameAs 2043962964 @default.
• W2043962964 citedByCount "16" @default.
• W2043962964 countsByYear W20439629642012 @default.
• W2043962964 countsByYear W20439629642013 @default.
• W2043962964 countsByYear W20439629642014 @default.
• W2043962964 countsByYear W20439629642015 @default.
• W2043962964 countsByYear W20439629642016 @default.
• W2043962964 countsByYear W20439629642017 @default.

• next